BACKGROUND: How to define poor growth response in the management of short growth hormone (GH)-treated children is controversial. AIM: Assess various criteria of poor response. SUBJECTS AND METHODS: Short GH-treated prepubertal children [n = 456; height (Ht) SD score (SDS) ≤-2] with idiopathic GH deficiency (IGHD, n = 173), idiopathic short stature (ISS, n = 37), small for gestational age (SGA, n = 54), organic GHD (OGHD, n = 40), Turner syndrome (TS, n = 43), skeletal dysplasia (n = 15), other diseases (n = 46) or syndromes (n = 48) were evaluated in this retrospective multicenter study. Median age at GH start was 6.3 years and Ht SDS -3.2. RESULTS: Median [25-75 percentile] first-year gain in Ht SDS was 0.65 (0.40-0.90) and height velocity (HtV) 8.67 (7.51-9.90) cm/year. Almost 50% of IGHD children fulfilled at least one criterion for poor responders. In 28% of IGHD children, Ht SDS gain was <0.5 and they had lower increases in median IGF-I SDS than those with Ht SDS >0.5. Only IGHD patients with peak stimulated growth hormone level <3 μg/l responded better than those with ISS. A higher proportion of children with TS, skeletal dysplasia or born SGA had Ht SDS gain <0.5. CONCLUSION: Many children respond poorly to GH therapy. Recommendations defining a criterion may help in managing short stature patients.
BACKGROUND: How to define poor growth response in the management of short growth hormone (GH)-treated children is controversial. AIM: Assess various criteria of poor response. SUBJECTS AND METHODS: Short GH-treated prepubertal children [n = 456; height (Ht) SD score (SDS) ≤-2] with idiopathic GH deficiency (IGHD, n = 173), idiopathic short stature (ISS, n = 37), small for gestational age (SGA, n = 54), organic GHD (OGHD, n = 40), Turner syndrome (TS, n = 43), skeletal dysplasia (n = 15), other diseases (n = 46) or syndromes (n = 48) were evaluated in this retrospective multicenter study. Median age at GH start was 6.3 years and Ht SDS -3.2. RESULTS: Median [25-75 percentile] first-year gain in Ht SDS was 0.65 (0.40-0.90) and height velocity (HtV) 8.67 (7.51-9.90) cm/year. Almost 50% of IGHDchildren fulfilled at least one criterion for poor responders. In 28% of IGHDchildren, Ht SDS gain was <0.5 and they had lower increases in median IGF-ISDS than those with Ht SDS >0.5. Only IGHDpatients with peak stimulated growth hormone level <3 μg/l responded better than those with ISS. A higher proportion of children with TS, skeletal dysplasia or born SGA had Ht SDS gain <0.5. CONCLUSION: Many children respond poorly to GH therapy. Recommendations defining a criterion may help in managing short staturepatients.
Authors: G Migliaretti; S Ditaranto; C Guiot; S Vannelli; P Matarazzo; N Cappello; I Stura; F Cavallo Journal: J Endocrinol Invest Date: 2018-01-09 Impact factor: 4.256
Authors: Stefan Kaspers; Michael B Ranke; Donald Han; Jane Loftus; Hartmut Wollmann; Anders Lindberg; Mathieu Roelants; Joris Kleintjens Journal: Appl Health Econ Health Policy Date: 2013-06 Impact factor: 2.561
Authors: José I. Labarta; Michael B. Ranke; Mohamad Maghnie; David Martin; Laura Guazzarotti; Roland Pfäffle; Ekaterina Koledova; Jan M. Wit Journal: J Clin Res Pediatr Endocrinol Date: 2020-10-02